L J Patterson
Affiliation: National Institutes of Health
- The "STEP-wise" future of adenovirus-based HIV vaccinesL J Patterson
Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Curr Med Chem 18:3981-6. 2011..Finally, evaluation of replicating adenovirus vectors known to be capable of inducing potent cellular, humoral, and mucosal immunity will be vital to meeting our future goal of an effective HIV vaccine...
- Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virusM Robert-Guroff
Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4255, USA
J Virol 72:10275-80. 1998..These results demonstrate the potential of this combination vaccine strategy and suggest that vaccine protection against an HIV isolate relevant to infection of people is feasible...
- A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challengeL J Patterson
Basic Research Laboratory, National Cancer Institute, Bethesda, Maryland 20892, USA
AIDS Res Hum Retroviruses 17:837-49. 2001..In spite of the peptomer's strong immunogenicity and potential for induction of broadly protective immune responses, it was not effective as a subunit vaccine...
- Formation of HIV-1 envelope-hepatitis B core antigen hybrids with high affinity for CD4L J Patterson
Laboratory of Immunoregulation, Office of Vaccine Research and Review, FDA National Institutes of Health, NIH Campus Bldg 29, Bethesda, MD 20892, USA
Biochem Biophys Res Commun 285:639-43. 2001..By combining the immunogenicity of the carrier protein with the antigenicity of gp120, these hybrids may lead to modified HIV-1 antigens with enhanced immunogenicity...